CTOs on the Move

Seton Imaging

www.setonimaging.com

 
Seton Imaging is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Buffalo, NY. To find more information about Seton Imaging, please visit www.setonimaging.com
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Occulogix

Occulogix, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Occulogix, Inc. is based in Elliot Lake, ON. You can find more information on Occulogix, Inc. at www.occulogix.com

Kemin Industries

A nutritional ingredient manufacturer, Kemin is a privately held corporation, founded in 1961 by R.W. and Mary Nelson.

Autonomic Technologies

Welcome. Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache. The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.

Retreat Nursing Home

Retreat Nursing Home is a Monticello, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.